About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results.

Researchers

M Gogishvili, T Makharadze, T Melkadze, D Giorgadze, K Penkov, K Laktionov, E Kalinka, G Nemsadze, M Nechaeva, I Rozhkova, D A G McIntyre, X Jia, M Kaul, S Chua, K Gillis, F Seebach, H Magnan, E Kim, A Baramidze

Abstract

EMPOWER-Lung 3 Part 2, a phase 3, double-blind, placebo-controlled study, demonstrated substantial survival benefits with cemiplimab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 alterations. Here, we report 5-year results from the subgroup analysis of patients with programmed death-ligand 1 (PD-L1) expression ≥1%. Eligible patients were randomized 2 : 1 to receive histology-specific platinum-doublet chemotherapy plus cemiplimab 350 mg or placebo every 3 weeks for up to 108 weeks. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). This analysis focuses on patients with PD-L1 ≥1% with 5-year follow-up (last patient last visit: 27 February 2025). Of 327 patients with PD-L1 ≥1% (out of 466 in the overall study), 217 received cemiplimab plus chemotherapy and 110 received placebo plus chemotherapy. After median follow-up of 60.5 months, median OS for cemiplimab plus chemotherapy was 24.0 months [95% confidence interval (CI) 20.9-28.4] versus 12.1 months (95% CI 10.1-15.7) for placebo plus chemotherapy [hazard ratio (HR) 0.54, 95% CI 0.41-0.70, P < 0.0001); median PFS was 8.3 months (95% CI 6.7-10.8) versus 5.5 months (95% CI 4.3-6.2, HR 0.50, 95% CI 0.39-0.65, P < 0.0001), and the ORR was 48.4% versus 22.7%, respectively. Improved efficacy over placebo plus chemotherapy was observed across squamous and nonsquamous histologies, in both locally advanced and metastatic disease, and in patients with PD-L1 1%-49% and ≥50%. Grade ≥3 treatment-emergent adverse events occurred in 48.8% of patients receiving cemiplimab plus chemotherapy versus 27.5% receiving placebo plus chemotherapy. No new toxicities were identified. First-line cemiplimab plus chemotherapy continued to show durable clinical benefit versus placebo plus chemotherapy after 5 years of follow-up in PD-L1-positive advanced NSCLC.
Source: PubMed (PMID: 43035066)View Original on PubMed